tiprankstipranks
AMN Healthcare (AMN)
NYSE:AMN
Want to see AMN full AI Analyst Report?

AMN Healthcare Services (AMN) AI Stock Analysis

545 Followers

Top Page

AMN

AMN Healthcare Services

(NYSE:AMN)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 5.2)
Rating:53Neutral
Price Target:
$31.00
▼(-5.75% Downside)
Action:Reiterated
Date:08/07/26
AMN scores in the mid-range primarily due to improving but still volatile fundamentals (profitability recovery and solid cash generation tempered by multi-year margin/revenue swings and meaningful debt) and a constructive-but-conservative earnings outlook that embeds normalization after nonrecurring Q2 benefits. The score is pulled down by weak near-term technical signals (below key short-term moving averages with subdued RSI/Stoch) and limited valuation support given the negative P/E and no dividend yield data.
Positive Factors
Cash generation
Consistent TTM operating and free cash flow provides durable funding for working capital, debt reduction and technology investment. Strong cash conversion supports flexibility through healthcare demand cycles and funds reinvestment without relying on frequent external financing.
Negative Factors
Reliance on labor-disruption revenue
A large portion of recent revenue and margin upside came from unpredictable labor-disruption events that management says are unlikely to recur. This reliance weakens revenue visibility and makes recent performance less indicative of sustainable demand or margin levels.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Consistent TTM operating and free cash flow provides durable funding for working capital, debt reduction and technology investment. Strong cash conversion supports flexibility through healthcare demand cycles and funds reinvestment without relying on frequent external financing.
Read all positive factors

AMN Healthcare Services Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Chart InsightsNurse & Allied has been the most volatile line—peaking with labor‑disruption windfalls and then normalizing to a lower, steadier base; management says underlying travel and allied demand is actually growing modestly ex‑event, but continued reliance on unpredictable disruption revenue creates earnings and cash‑normalization risk. Physician & Leadership is stable but under pressure from softer locums demand and third‑party channel pricing. Technology & Workforce is the structural weak spot—declining markedly and guided lower y/y despite sequential improvement as AMN leans on AI/WorkWise to stabilize trends.
Data provided by:The Fly

AMN Healthcare Services (AMN) vs. SPDR S&P 500 ETF (SPY)

AMN Healthcare Services Business Overview & Revenue Model

Company Description
AMN Healthcare Services, Inc. (AMN) specializes in delivering comprehensive workforce solutions and staffing services to hospitals and healthcare facilities throughout the United States. Its operations are structured across three primary segments:...
How the Company Makes Money
AMN primarily makes money by providing staffing and workforce solutions to healthcare providers and charging fees tied to the placement and deployment of clinicians. Key revenue streams generally include: (1) Nurse and allied staffing—AMN recruits...

AMN Healthcare Services Earnings Call Summary

Earnings Call Date:Aug 06, 2026
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call presented multiple strong operational and financial highlights — revenue beat, sizable adjusted EBITDA and EPS improvement, robust cash balance, low leverage, strong Nurse & Allied performance, accelerated travel and allied volumes, and meaningful product adoption and search momentum. Several targeted acquisitions and improved operational automation/AI capabilities support longer-term growth. Offsetting these positives are notable near-term headwinds: Technology & Workforce Solutions and language services revenue declines and pricing pressure, a weaker locum/physician segment, and the fact that the Q2 outperformance was partly driven by nonrecurring items that will not repeat in Q3. Management provided conservative Q3 guidance reflecting normalization. Overall, the company appears well-positioned financially and operationally, with manageable short-term challenges and a constructive outlook into 2027.
Positive Updates
Consolidated Revenue Beat
Second quarter consolidated revenue of $673 million, which was 6% above the high end of guidance and grew 2% year-over-year.
Negative Updates
Technology & Workforce Solutions Revenue Decline
TWS revenue was $87 million, down 15% year-over-year (down 11% ex-SmartSquare divestiture); segment gross margin 48.6% declined sequentially and year-over-year.
Read all updates
Q2-2026 Updates
Negative
Consolidated Revenue Beat
Second quarter consolidated revenue of $673 million, which was 6% above the high end of guidance and grew 2% year-over-year.
Read all positive updates
Company Guidance
Management guided third-quarter consolidated revenue of $640–$655 million, gross margin of 27.0–27.5%, reported SG&A of 22.0–22.5% of revenue, operating margin of 0.2–0.8% and adjusted EBITDA margin of 6.5–7.0%; segment guidance included Nurse & Allied revenue growth of 9–11% year‑over‑year (with travel nurse and allied volume each expected to be better than +10% YoY), Physician & Leadership revenue down 5–7% YoY, and Technology & Workforce Solutions revenue down 11–13% YoY. The guide embeds roughly $7–8 million of strike‑related revenue for Q3, and management expects to exit the quarter with at least $225 million of cash (assuming remaining client deposits are repaid), with total debt of $750 million and covenant leverage of ~1.5x; modest share repurchases to offset dilution were also indicated.

AMN Healthcare Services Financial Statement Overview

Summary
Financials are stabilizing after a weak period: TTM shows a sharp revenue rebound (+44.1%) and a return to positive profitability (~3.1% net margin), with solid operating/free cash flow generation (OCF ~$471M; FCF ~$455M). Offsetting this, profitability remains well below prior-cycle peaks and results have been volatile over 2023–2025; debt is still sizable even as leverage has improved versus prior years.
Income Statement
54
Neutral
Balance Sheet
56
Neutral
Cash Flow
62
Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.43B2.73B2.98B3.79B5.24B3.98B
Gross Profit954.26M774.06M919.38M1.25B1.72B1.31B
EBITDA276.67M101.13M71.11M499.36M784.21M581.70M
Net Income21.59M-95.70M-146.98M210.68M444.05M327.39M
Balance Sheet
Total Assets2.36B2.09B2.42B2.92B2.89B3.13B
Cash, Cash Equivalents and Short-Term Investments361.84M33.97M10.65M32.94M64.52M180.93M
Total Debt742.93M803.20M1.10B1.35B860.96M867.07M
Total Liabilities1.62B1.45B1.71B2.09B1.84B1.97B
Stockholders Equity741.28M642.11M706.62M831.26M1.04B1.16B
Cash Flow
Free Cash Flow454.91M233.83M239.53M266.78M572.81M251.69M
Operating Cash Flow470.76M269.46M320.42M372.17M653.73M305.36M
Investing Cash Flow31.23M4.30M-79.94M-412.49M-170.71M-107.40M
Financing Cash Flow-183.96M-295.89M-259.45M10.73M-591.87M-34.90M

AMN Healthcare Services Technical Analysis

Technical Analysis Sentiment
Negative
Last Price32.89
Price Trends
50DMA
32.16
Negative
100DMA
26.92
Positive
200DMA
22.58
Positive
Market Momentum
MACD
0.16
Positive
RSI
39.74
Neutral
STOCH
30.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMN, the sentiment is Negative. The current price of 32.89 is below the 20-day moving average (MA) of 33.48, above the 50-day MA of 32.16, and above the 200-day MA of 22.58, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 39.74 is Neutral, neither overbought nor oversold. The STOCH value of 30.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMN.

AMN Healthcare Services Risk Analysis

AMN Healthcare Services disclosed 29 risk factors in its most recent earnings report. AMN Healthcare Services reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

AMN Healthcare Services Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
83
Outperform
$2.16B21.359.57%19.55%21.54%
76
Outperform
$1.60B13.4724.12%5.22%1109.87%
71
Outperform
$2.18B12.8719.89%-2.25%
69
Neutral
$2.04B7.41241.47%20.49%4335.46%
62
Neutral
$1.40B45.309.23%36.76%11.22%
53
Neutral
$1.30B-39.10-4.98%19.87%79.93%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AMN
AMN Healthcare Services
30.80
13.88
82.03%
ADUS
Addus Homecare
118.78
9.68
8.87%
HCSG
Healthcare Services
22.05
8.32
60.60%
MD
Pediatrix Medical Group
26.51
12.03
83.08%
PNTG
Pennant Group
39.06
14.94
61.94%
AVAH
Aveanna Healthcare Holdings
9.31
3.50
60.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 07, 2026